Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Dose-Escalation DLI After T-Cell Depleted SCT
NCT01839916Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Apr 2013
- Primary completion
- Aug 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocyte infusion in hematologic malignancy, sponsored by University of Chicago. Primary endpoint: Percentage of Patients Who Are Able to Receive at Least One DLI Treatment up to 2 years. Started Apr 2013; status: completed.
02
Drugs
donor lymphocyte infusion
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01839916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839916.